No Cure Exists for Autoimmune Atrophic Gastritis
There is no cure for autoimmune atrophic gastritis (AAG). The condition involves irreversible destruction of gastric parietal cells by autoimmune mechanisms, leading to permanent loss of gastric acid production and progressive atrophy of the corpus mucosa 1. Management focuses on surveillance for complications and replacement of deficient nutrients rather than reversing the underlying autoimmune process.
Why AAG Cannot Be Cured
The autoimmune destruction of parietal cells in AAG represents a "point-of-no-return" where gastric mucosal damage cannot be reversed 1. Unlike H. pylori-associated atrophic gastritis where some mucosal restoration may occur after bacterial eradication, the autoimmune process in AAG causes permanent glandular loss and replacement with connective tissue or metaplastic epithelium 1.
Critical Distinction: H. pylori vs. Pure Autoimmune Disease
An important caveat: Some patients diagnosed with AAG may have concurrent H. pylori infection, and in rare cases, what appears to be AAG may actually be H. pylori-triggered autoimmune gastritis in its early, pre-atrophic stage. In these specific cases, H. pylori eradication can lead to healing of the active autoimmune process 2, 3, 4. However, this represents a distinct clinical entity—active, non-atrophic autoimmune gastritis—rather than established AAG with complete parietal cell destruction.
All patients with AAG should still be tested for H. pylori and treated if positive 1, as eradication may reduce gastric cancer risk even if it cannot reverse established atrophy 1.
Management Strategy (Not Cure)
Since cure is not possible, the clinical approach centers on:
1. Nutritional Replacement
- Vitamin B12 supplementation for pernicious anemia (a late-stage manifestation) 1
- Iron replacement for deficiency 1
- Evaluate for both deficiencies regardless of symptoms 1, 2
2. Cancer Surveillance
- Screen for type 1 gastric neuroendocrine tumors (gNENs) with upper endoscopy 1
- Remove small neuroendocrine tumors endoscopically
- Surveillance endoscopy every 1-2 years depending on gNEN burden 1
- Monitor for gastric adenocarcinoma risk, though optimal surveillance intervals remain unclear 1
3. Screen for Associated Autoimmune Conditions
- Check for autoimmune thyroid disease, present in up to one-third of AAG patients 1
- Consider other autoimmune disorders (type 1 diabetes, etc.) 1
4. Confirm Diagnosis
- Check antiparietal cell antibodies (sensitive but can have false positives) 1
- Check anti-intrinsic factor antibodies (more specific) 1
- Histopathology showing corpus-predominant atrophy with loss of parietal cells 1
Emerging Concepts (Not Yet Standard Practice)
Some theoretical approaches have been proposed but lack clinical validation:
- Acid replacement with betaine hydrochloride to address achlorhydria and potentially reduce hypergastrinemia 5
- Netazepide (gastrin/CCK2 receptor antagonist) is the only agent tested in clinical trials for reducing gNEN risk 6
- Targeting ER stress, autophagy, or microbiome remain preclinical 6
Common Pitfall to Avoid
Do not prescribe proton pump inhibitors or other acid suppressants to patients with AAG. These patients already have achlorhydria from parietal cell destruction; further acid suppression worsens the consequences of gastric atrophy, including hypergastrinemia and increased cancer risk 5.